Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
14,353 people get ABT articles and Market Currents by email alert.
Get email alerts on ABT »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
-
-
At These Levels, Covidien Has Room To RunStephen Barnes • Tue, Apr 30 -
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
Abbott Hopes Mitral Repair Will Be The New TAVIEP Vantage • Wed, Feb 27 -
-
-
-
-
-
-
-
Abbott Earnings Preview: What We Are WatchingTrefis • Tue, Jan 22
-
-
-
-
-
-
-
-
-
-
-
-
At These Levels, Covidien Has Room To RunStephen Barnes • Tue, Apr 30
-
-
-
-
-
-
-
-
-
Abbott Laboratories' Management Presents HCV Program Update (Transcript)Mon, Nov 12, 2012
-
Abbott Laboratories Q1 2010 Earnings Call TranscriptWed, Apr 21, 2010
-
Abbott Laboratories Q4 2009 Earnings Call TranscriptWed, Jan 27, 2010
-
Abbott Laboratories, Q3 2009 Earnings Call TranscriptWed, Oct 14, 2009
-
Abbott Laboratories, Q2 2009 Earnings Call TranscriptWed, Jul 15, 2009 • 1 Comment
-
Abbott Laboratories Q1 2009 Earnings Call TranscriptFri, Apr 17, 2009
-
Abbott Laboratories Q4 2008 Earnings Call TranscriptWed, Jan 21, 2009
-
at CNBC.com (May 17, 2013)
-
at CNBC.com (May 17, 2013)
-
at CNBC.com (May 13, 2013)
-
at MarketWatch.com (Apr 30, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at CNBC.com (Apr 22, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at CNBC.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 16, 2013)
-
at CNBC.com (Apr 14, 2013)
-
at CNBC.com (Apr 3, 2013)
-
at CNBC.com (Apr 2, 2013)
-
at MarketWatch.com (Mar 22, 2013)
-
at CNBC.com (Mar 20, 2013)
-
at CNBC.com (Mar 11, 2013)
-
at CNBC.com (Feb 14, 2013)
-
at MarketWatch.com (Jan 30, 2013)
-
at MarketWatch.com (Jan 23, 2013)
ABT vs. ETF Alternatives
Company Description
Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott's* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of health care products.
Abbott has four reportable revenue segments: Pharmaceutical Products, Diagnostic... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, November 5, 2012, 9:39 AM Bypass surgery is more effective than drug-coated stents in preventing heart attacks and deaths in diabetics with more than one diseased artery, a five-year study shows. However, there were more strokes among bypass patients. Still, the data could lead to changes in treatment recommendations for thousands of people, hurting the profits of stent makers such as Abbott Labs (ABT -0.3%), Boston Scientific (BSX) and Medtronic (MDT -0.2%). Comment! [Healthcare]
- Friday, November 2, 2012, 5:44 AM Having been prevented from issuing bonds early this week because of Hurricane Sandy, companies jumped into the market with a vengeance yesterday, raising almost $12B worth of debt. BP (BP) with a $3B deal and GD (GD) with $2.4B led the way, although AbbVie - soon to be spun off from Abbott Labs (ABT) - delayed a $10B offering until next week. 1 Comment [Global & FX, U.S. Economy]
- Sunday, October 28, 2012, 3:29 AM AbbVie, which is due to be spun off from Abbott Labs (ABT) on Jan 1, is set to this week sell over $10B in bonds in what would be one of the 10 largest U.S. investment-grade debt offerings in recent memory, the WSJ reports. AbbVie will use the money pay a dividend to Abbot, which will itself use the cash to pay off its own debt. 3 Comments [Healthcare]
- Tuesday, October 23, 2012, 9:42 AM Seattle Genetics (SGEN -3.1%) expands a partnership with Abbott (ABT -1.1%) in which the latter will pay Seattle an upfront fee of $25M to use its antibody-drug conjugate to help develop treatments for cancer. Seattle will also receive maintenance fees and research support payments, up to $220M in milestones, and royalties (PR.) Comment! [Healthcare]
- Thursday, October 18, 2012, 9:31 AM Reata Pharmaceuticals has told Abbott Labs (ABT -4.4%) that it's discontinuing Phase 3 trials of bardoxolone methyl in patients with advanced chronic kidney disease and Type 2 diabetes following "excess serious adverse events and mortality." Reata and Abbott, which holds the rights to the drug outside the U.S., will examine the data to see whether it can still be developed. (8-K) Comment! [On the Move, Healthcare]
- Wednesday, October 17, 2012, 3:25 PM Abbott Laboratories (ABT -4%) says it's laying off about 550 workers and plans several hundred more layoffs throughout 2013, citing "evolving business needs." The disclosure comes on the back of a Q3 earnings report earlier today showing surging profit amid a double-digit percentage fall in expenses. 5 Comments [Healthcare]
- Wednesday, October 17, 2012, 9:00 AM More on Abbott Labs (ABT) Q3: net profit soars to $1.94B from $303M as operating margin soars to 20.4% from 6.1%. Total op costs -16%, with last year's SG&A expenses including $1.5B of litigation reserves. Abbot narrows FY EPS guidance to $5.06-$5.08 from $5-$5.10 previously and vs. consensus of $5.06. Says the separation into two companies is on track for Jan. 1. Comment! [Earnings, Healthcare]
- Wednesday, October 17, 2012, 7:46 AM Abbott Laboratories (ABT): Q3 EPS of $1.30 beats by $0.02. Revenue of $9.77B (+2% Y/Y) misses by $160M. (PR) Comment! [Earnings, Healthcare]
- Wednesday, October 17, 2012, 12:05 AM Notable earnings before Wednesday’s open: ABT, ASML, BAC, BK, BLK, CHKP, CMA, DGX, DOV, HAL, KCG, MMR, MTB, PEP, STJ, STP, SWK, TXT, USB Comment! [Earnings]
- Tuesday, October 16, 2012, 5:30 PM Notable earnings before Wednesday’s open: ABT, ASML, BAC, BK, BLK, CHKP, CMA, DGX, DOV, HAL, KCG, MMR, MTB, PEP, STJ, STP, SWK, TXT, USB 3 Comments [Earnings]
- Tuesday, October 16, 2012, 12:36 PM Achillion (ACHN +4.6%) gains on a price target increase to $17 from $12 at Deutsche Bank. The firm says liver abstracts from Bristol-Myers (BMY +0.6%) and Abbott (ABT +0.1%) bode well for the future success of ACHN's two drug combo regimens for the treatment of hepatitus C virus. The firm made similar comments yesterday about Gilead (GILD +1.6%). Comment! [Healthcare, On the Move]
- Monday, October 15, 2012, 1:50 PM Gilead (GILD -0.9%) slips a bit today after Bristol-Myers (BMY +3.2%) and Abbott (ABT +3.7%) both reported favorable study results for their HCV drugs (I,II). Deutsche Bank defends the stock , saying the results of these studies show that utilizing different drug combinations yields more effective HCV treatments, and that this data actually bodes well for GILD's 7977-based class combos, for which it expects the drug developer to yield similar results. Comment! [Healthcare, On the Move]
- Monday, October 15, 2012, 12:58 PM Abbott (ABT +3.4%) moves up after initial results from its "Aviator" Phase 2b study of its interferon-free, investigational regimen for the treatment of hepatitis C indicated that 99% of the "treatment naive" HCV patients - those who had never been previously treated for the virus - showed a sustained virological response. Additionally, 93% of patients in the study who had previously been unsuccessfully treated for HCV also showed sustained virological response. 2 Comments [Healthcare, On the Move]
- Friday, September 28, 2012, 2:13 PM The FDA is expanding the approved use of Abbott's (ABT -1%) Humira to include treatment of moderate-to-severe ulcerative colitis in adults, when immunosuppressant medicines have not worked. The drug is currently approved for use in reducing the signs and symptoms of rheumatoid arthritis. Comment! [Healthcare]
- Wednesday, September 26, 2012, 11:37 AM Abbott (ABT -0.4%) says its humanised monoclonal antibody for the treatment of glioma has been granted orphan designation by the European Commission. Glioma affects approximately 1 in 10K people in the European Union, or the equivalent of a total of around 51K people. Comment! [Healthcare, Global & FX]
- Wednesday, September 26, 2012, 7:56 AM The EU proposes tougher standards on medical devices and implants after investigations showed hundreds of thousands of women were at risk from substandard silicone implants. Independent assessment of manufacturers and increased product testing could result from the new legislation. 4 Comments [Healthcare]
-
- View all 0 replies
-
swingtrader427
Looking at ABT call spread today. Technicals and fundamentals look good and chart pattern was a narrow range bar indicating a tug of war. - View all 0 replies
-
- View all 0 replies
-
- View all 3 replies
-
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 3 replies
-
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 6 replies
-
-
Hillbilly Stock Star: I keep too much cash last year, this year heavy, EVN,VCSH, T, I guess we will see. Long.
-
- View all 8 replies
-
-
FortSumter: Andrew is right. I've noticed the same thing on the Yahoo Market Pulse (which pulls from stock twits).
-
- View all 3 replies
-
-
-
- View all 4 replies
-
-
-
- View all 3 replies
-
-
-
- View all 1 replies
-
-
- View all 6 replies
-
Clayton Rulli: i was gonna pinch some at 76 a few days back but got greedy and missed the boat! -
-
- View all 2 replies
-
-
-
- View all 9 replies
-
-
1980XLS-2.0: #1 strategic target in the event of Iran conflict, will be gasoline refineries. Count on it. If it happens, might as well make some$$$$
-
Jim Van Meerten
ABT - 96% Barchart technical buy signal - 14 new highs and up 4.34% in the last month - Relative Strength Index 64.62% - View all 6 replies
-
-
-
- View all 2 replies
-
-
-
- View all 1 replies
-
-
- View all 2 replies
-
-
neobliviscar: MCD cannonball !!! Me loved it longtime baby, but the Mac is all played out for a while. May be daytradeable in a range.
-
- View all 2 replies
-
-
-
- View all 4 replies
-
Hillbilly Stock Star: MRO.......apparently on bankster "buy list" for 2012! LOL! Long and overweight.
-